



## Natural Compounds with Activity against Ovarian Cancer: In Memory of Michelle Kendall, an Ovarian Cancer Warrior (1973-2021)

Guest Editor:

**Prof. Dr. Hinanit Koltai**

Institute of Plant Sciences,  
Agriculture Research  
Organization, Volcani Institute,  
Rishon LeZion 7505101, Israel

Deadline for manuscript  
submissions:

**closed (1 March 2023)**

### Message from the Guest Editor

Ovarian cancer (OC) is the second most common and the most lethal gynecologic malignancy in the Western world. Late-stage ovarian cancer is incurable in the majority of cases. Most women have advanced disease, for which the standard of care remains as surgery and platinum-based cytotoxic chemotherapy. Additional treatments include targeted therapies that target specifically cancer-related processes necessary for tumor growth, division and spread. Nevertheless, in about 80% of cases, on average, disease relapse is expected after 24 months, and ultimately, multi-drug resistance develops, with very few women surviving five years after diagnosis. A large number of plant compounds have anti-cancer activity. Some plants (e.g., *Cannabis sativa*, *Moringa oleifera*, *Camellia sinensis*, *Pao pereira*, *Xylocarpus granatum*, *Margaritaria discoidea*, and *Rauwolfia vomitoria*) and molecules (e.g., phytocannabinoids, resveratrol, tetrandrine, naringin, and soy protein) were examined for their anti-OC activity in vivo, in vitro, and in clinical trials.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Thomas J. Schmidt**

Institute of Pharmaceutical  
Biology and Phytochemistry,  
University of Münster,  
Corrensstrasse 48, D-48149  
Münster, Germany

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

## Contact Us

*Molecules* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/molecules](http://mdpi.com/journal/molecules)  
[molecules@mdpi.com](mailto:molecules@mdpi.com)  
[X@Molecules\\_MDPI](https://twitter.com/Molecules_MDPI)